RADIATE: more treatment options for patients with an inadequate response to tumor necrosis factor antagonists (Q83080013)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19107112%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

title

RADIATE: more treatment options for patients with an inadequate response to tumor necrosis factor antagonists (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19107112%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

author name string

Ernest Choy

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19107112%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

publication date

23 December 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19107112%20AND%20SRC:MED&resulttype=core&format=json

Nature Clinical Practice Rheumatology

19 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19107112%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

volume

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19107112%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19107112%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

66-67

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19107112%20AND%20SRC:MED&resulttype=core&format=json

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

19 January 2020

cites work

1 reference

12 December 2020

Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab

1 reference

12 December 2020

1 reference

12 December 2020

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

1 reference

12 December 2020

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

1 reference

12 December 2020

Outcomes after switching from one anti–tumor necrosis factor α agent to a second anti–tumor necrosis factor α agent in patients with rheumatoid arthritis: Results from a large UK national cohort study

1 reference

12 December 2020

Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition

1 reference

12 December 2020

B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents

1 reference

12 December 2020

Identifiers

DOI

10.1038/NCPRHEUM0984

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19107112%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference